OncoSec Medical Inc. (OTCQB:ONCS), a company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy to treat solid
tumors, today announced that Punit Dhillon, President and CEO, will
present at “TEN”; Noble Financial Capital Markets’ Tenth Annual Equity
Conference, at Club Med in Sandpiper Bay, Florida, on Tuesday, January
21 at 1:30 p.m. (EST) in Room 1.
At the time of the presentation, a live audio and high-definition video
webcast of OncoSec’s presentation will be available at the following
link: http://noble.mediasite.com/mediasite/Play/43f884803e304fcabf7f2cca45be07d51d
OncoSec recommends registering at least 10 minutes prior to the start of
the presentation to ensure timely access. Participants will require a
Microsoft Silverlight viewer (a free download from the presentation
link) in order to participate.
About Noble Financial Capital Markets
Noble Financial Capital Markets was established in 1984; 2014 marks its
30th Anniversary. Noble Financial is an equity research driven,
full-service, investment banking boutique focused on life sciences,
technology and media, emerging growth, companies. The company has
offices in Boston, Los Angeles, and Boca Raton, FL. In addition to
non-deal road shows and sector-specific conferences throughout the year,
Noble Financial hosts its large format annual equity conference in
January in South Florida featuring 120 - 150 presenting companies from
across North America and total attendance of close to 600. For more
information: www.noblefcm.com
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its
advanced-stage ImmunoPulse DNA-based immunotherapy and NeoPulse therapy
to treat solid tumors. ImmunoPulse and NeoPulse therapies address an
unmet medical need and represent a potential solution, for less invasive
and less expensive therapies that can minimize the detrimental effects
resulting from currently available cancer treatments such as surgery,
systemic chemotherapy and other treatment alternatives. OncoSec
Medical's core technology is based upon its proprietary use of
an electroporation platform to enhance the delivery and uptake of a
locally delivered DNA-based immunocytokine (ImmunoPulse) or
chemotherapeutic agent (NeoPulse). Treatment of various solid
cancers using these targeted anti-cancer agents has
demonstrated selective destruction of cancerous cells while potentially
sparing healthy normal tissues during early and late stage clinical
trials. OncoSec's clinical programs include three Phase II clinical
trials for ImmunoPulse targeting lethal skin cancers. More information
is available at http://www.oncosec.com/.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such "forward-looking statements." Forward-looking statements
are based on management's current preliminary expectations and are
subject to risks and uncertainties, which may cause our results to
differ materially and adversely from the statements contained herein.
Some of the potential risks and uncertainties that could cause actual
results to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or commercialize new
products, uncertainties inherent in pre-clinical studies and clinical
trials, unexpected new data, safety and technical issues, competition,
and market conditions. These and additional risks and uncertainties are
more fully described in OncoSec Medical's filings with the Securities
and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are
made. OncoSec Medical disclaims any obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.
Copyright Business Wire 2014